|

Iomab-B Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 131I-Apamistamab, Iomab-ACT

Pipeline

Phase 1/2: 1

Top Sponsors

  • University of Texas Southwestern Medical Center1

Indications

  • Non-hodgkin Lymphoma1
  • Diffuse Large B-Cell Lymphoma1
  • Cancer1

Dallas, Texas1 trial

Study of IOMAB-ACT Followed by CAR-T Cell Therapy for Patients Relapsed or Refractory (Diffuse Large B-cell Lymphoma

University of Texas Southwestern Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.